- Home
- COEP vs ATYR Comparison
COEP vs ATYR Comparison
Compare COEP & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COEP
- ATYR
- Stock Information
- Founded
- COEP 2017
- ATYR 2005
- Country
- COEP United States
- ATYR United States
- Employees
- COEP N/A
- ATYR N/A
- Industry
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- COEP Health Care
- ATYR Health Care
- Exchange
- COEP Nasdaq
- ATYR Nasdaq
- Market Cap
- COEP 72.1M
- ATYR 86.3M
- IPO Year
- COEP N/A
- ATYR 2015
- Fundamental
- Price
- COEP $14.79
- ATYR $0.81
- Analyst Decision
- COEP
- ATYR Buy
- Analyst Count
- COEP 0
- ATYR 6
- Target Price
- COEP N/A
- ATYR $8.88
- AVG Volume (30 Days)
- COEP 34.6K
- ATYR 6.7M
- Earning Date
- COEP 11-10-2025
- ATYR 11-11-2025
- Dividend Yield
- COEP N/A
- ATYR N/A
- EPS Growth
- COEP N/A
- ATYR N/A
- EPS
- COEP N/A
- ATYR N/A
- Revenue
- COEP $263,555.00
- ATYR N/A
- Revenue This Year
- COEP N/A
- ATYR $420.85
- Revenue Next Year
- COEP N/A
- ATYR $1,513.40
- P/E Ratio
- COEP N/A
- ATYR N/A
- Revenue Growth
- COEP N/A
- ATYR N/A
- 52 Week Low
- COEP $2.31
- ATYR $0.68
- 52 Week High
- COEP $19.19
- ATYR $7.29
- Technical
- Relative Strength Index (RSI)
- COEP 46.31
- ATYR 27.90
- Support Level
- COEP $14.50
- ATYR $0.94
- Resistance Level
- COEP $15.49
- ATYR $1.02
- Average True Range (ATR)
- COEP 0.73
- ATYR 0.06
- MACD
- COEP -0.10
- ATYR 0.07
- Stochastic Oscillator
- COEP 14.91
- ATYR 6.36
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.